11.07.14
Emergent BioSolutions
3Q Revenues: $138.0 million (+55%)
3Q Earnings: $21.8 million (+61%)
YTD Revenues: $302.2 million (+41%)
YTD Earnings: $6.6 million (earnings were $15.9 in 3Q13)
Comments: BioThrax sales were $66.0 million, down 5%. Other biodefense revenue was $11.7 million, up 67%. Revenues from contract manufacturing operations, gained with the Cangene acquisition in 1Q14, were $9.4 million. These operations comprise services including biopharma product development, product filling, lyophilization and stability studies. R&D expenses were $44.2 million, up 53% primarily attributable to additional product development programs from the Cangene acquisition.
3Q Revenues: $138.0 million (+55%)
3Q Earnings: $21.8 million (+61%)
YTD Revenues: $302.2 million (+41%)
YTD Earnings: $6.6 million (earnings were $15.9 in 3Q13)
Comments: BioThrax sales were $66.0 million, down 5%. Other biodefense revenue was $11.7 million, up 67%. Revenues from contract manufacturing operations, gained with the Cangene acquisition in 1Q14, were $9.4 million. These operations comprise services including biopharma product development, product filling, lyophilization and stability studies. R&D expenses were $44.2 million, up 53% primarily attributable to additional product development programs from the Cangene acquisition.
